×
About 24,130 results
Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
https://www.nejm.org/doi/full/10.1056/NEJMoa1912388?query=featured_home
New England Journal of Medicine; Tardif JC et al

Nov 16th, 2019 - Experimental and clinical evidence support the role of inflammation in atherosclerosis and its complications. Colchicine is an orally administered, potent antiinflammatory medication that is indicated for the treatment of gout and pericarditis.

Top 10 Medical Innovations for 2020, According to Cleveland Clinic
https://www.medscape.com/viewarticle/920936
Medscape

Nov 9th, 2019 - A dual-acting osteoporosis drug, minimally invasive mitral valve surgery, and a new treatment for peanut allergies are among the medical advances that will significantly transform the medical field and improve care for patients in the coming year, according to the Cleveland Clinic's list of top 10 medical innovations for 2020.

Scientists design device for oral delivery of injections
https://www.nih.gov/news-events/nih-research-matters/scientists-design-device-oral-delivery-injections

Oct 28th, 2019 - Biologic drugs are complex medications produced from living organisms or their parts. They include vaccines and drugs to treat conditions like rheumatoid arthritis, psoriasis, and cancer. Some biologic drugs, like insulin, can only be delivered by injection. If taken by mouth, stomach acid would destroy the drug before it could take effect.

Do High-Dose Statins Increase the Risk for Osteoporosis?
https://www.medscape.com/viewarticle/919825

Oct 13th, 2019 - The protective effect of statin therapy on bone health that has been demonstrated in some studies may be dose-related, and although low doses are associated with a reduced risk for osteoporosis, high doses were linked to an increased risk of the bone disease in new research.

FDA approves first treatment for children with rare diseases that cause inflammation of small blood vessels
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-children-rare-diseases-cause-inflammation-small-blood-vessels

Sep 26th, 2019 - The U.S. Food and Drug Administration today approved Rituxan (rituximab) injection to treat granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children 2 years of age and older in combination with glucocorticoids (steroid hormones). It is the first approved treatment for children with these rare vasculitis diseases, in which a patient’s small blood vessels become infla...

Psoriatic Arthritis - StatPearls
https://www.ncbi.nlm.nih.gov/books/NBK547710/

Sep 19th, 2019 - Psoriatic arthritis (PsA) is chronic inflammatory arthritis associated with psoriasis (PsO) and found in about 20 to 30% of such patients.[1] It shares many clinical features with other spondyloarthropathies and also rheumatoid arthritis (RA). It is usually seronegative, but a small percentage of patients may be positive for rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodi...

FDA approves first treatment for patients with rare type of lung disease
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-rare-type-lung-disease

Sep 5th, 2019 - The U.S. Food and Drug Administration today approved Ofev (nintedanib) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD. It is the first FDA-approved treatment for this rare lung condition.

Unraveling the Safety Profile of Proton-Pump Inhibitors
https://www.jwatch.org/na49660/2019/08/19/unraveling-safety-profile-proton-pump-inhibitors
Journal Watch;

Aug 19th, 2019 - Proton-pump inhibitors (PPIs) provide important clinical benefits for many patients. However, observational studies have suggested an association between PPI use and a variety of adverse events, including dementia, osteoporosis, bone fractures, micronutrient deficiencies, pneumonia, spontaneous bacterial peritonitis, kidney disease, and enteric infections. We have observed that some patients wi...

AbbVie Receives FDA Approval of RINVOQ™ (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe AbbVie Receives FDA Approval of RINVOQ™ (upadacitinib), an Oral JAK Inhibitor F...
https://news.abbvie.com/news/press-releases/abbvie-receives-fda-approval-rinvoq-upadacitinib-an-oral-jak-inhibitor-for-treatment-moderate-to-severe-rheumatoid-arthritis.htm?_ga=2.79140499.665850950.1566223698-1470367535.1566223698

Aug 15th, 2019 - AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ™ (upadacitinib), a 15 mg, once-daily oral Janus kinase (JAK) inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX-IR).1 R...

ACG Clinical Guideline: Hereditary Hemochromatosis
https://journals.lww.com/ajg/Fulltext/2019/08000/ACG_Clinical_Guideline__Hereditary_Hemochromatosis.11.aspx
Kowdley, K. et. al.

Aug 1st, 2019 - Hereditary hemochromatosis (HH) is one of the most common genetic disorders among persons of northern European descent. There have been recent advances in the diagnosis, management, and treatment of HH. The availability of molecular diagnostic testing for HH has made possible confirmation of the diagnosis for most patients. Several genotype-phenotype correlation studies have clarified the diffe...

FDA clears new indications for existing Lyme disease tests that may help streamline diagnoses
https://www.fda.gov/news-events/press-announcements/fda-clears-new-indications-existing-lyme-disease-tests-may-help-streamline-diagnoses

Jul 28th, 2019 - Today, the U.S. Food and Drug Administration cleared for marketing four previously cleared tests with new indications to aid in the diagnosis of Lyme disease. The tests cleared today are the first time that a test has been indicated to follow a new testing paradigm in which two tests called enzyme immunoassays (EIA) are run concurrently or sequentially, rather than the current two-step process ...

FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR)
https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and

Jul 25th, 2019 - The U.S. Food and Drug Administration has approved new warnings about an increased risk of blood clots and of death with the 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR), which is used in patients with ulcerative colitis. In addition, the approved use of tofacitinib for ulcerative colitis will be limited to certain patients who are not treated effectively or who experience severe...

Xeljanz, Xeljanz XR (tofacitinib): Drug Safety Communication - Due to an Increased Risk of Blood Clots and Death with Higher Dose
https://www.fda.gov/safety/medwatch-safety-alerts-human-medical-products/xeljanz-xeljanz-xr-tofacitinib-drug-safety-communication-due-increased-risk-blood-clots-and-death

Jul 25th, 2019 - AUDIENCE: Patient, Health Professional, Pharmacy, Gastroenterology, Rheumatology ISSUE: FDA has approved new warnings about an increased risk of blood clots and of death with the 10 mg twice daily dose of Xeljanz, Xeljanz XR (tofacitinib), which is used in patients with ulcerative colitis. In addition, the approved use of tofacitinib for ulcerative colitis will be limited to certain patients...

FDA Approves Samsung Bioepis' HADLIMA™ (adalimumab-bwwd)
https://www.businesswire.com/news/home/20190723006033/en/FDA-Approves-Samsung-Bioepis-HADLIMA%E2%84%A2-adalimumab-bwwd

Jul 23rd, 2019 - Samsung Bioepis Co., Ltd. today announced that the US Food and Drug Administration (FDA) has approved HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® i (adalimumab), for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis and plaque psoriasis. Please see below the full indicatio...

FDA Approves Pfizer’s Biosimilar, Ruxience™ (Rituximab-pvvr), For Certain Cancers And Autoimmune Conditions
https://www.pfizer.com/news/press-release/press-release-detail/fda_approves_pfizer_s_biosimilar_ruxience_rituximab_pvvr_for_certain_cancers_and_autoimmune_conditions

Jul 22nd, 2019 - Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved RUXIENCE™ (rituximab-pvvr), a biosimilar to Rituxan® (rituximab),1 for the treatment of adult patients with non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), and granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).2 “Biosimilars like RUXIENCE h...

FDA approves first generics of Lyrica
https://www.fda.gov/news-events/press-announcements/fda-approves-first-generics-lyrica

Jul 21st, 2019 - On July 19, the U.S. Food and Drug Administration approved multiple applications for first generics of Lyrica (pregabalin) for the management of neuropathic pain associated with diabetic peripheral neuropathy, for the management of postherpetic neuralgia, as an adjunctive therapy for the treatment of partial onset seizures in patients 17 years of age and older, for the management of fibromyalgi...

Rheumatoid arthritis - Genetics Home Reference - NIH
https://ghr.nlm.nih.gov/condition/rheumatoid-arthritis

Jul 15th, 2019 - Rheumatoid arthritis is a disease that causes chronic abnormal inflammation, primarily affecting the joints. The most common signs and symptoms are pain, swelling, and stiffness of the joints. Small joints in the hands and feet are involved most often, although larger joints (such as the shoulders, hips, and knees) may become involved later in the disease. Joints are typically affected in a sym...

Acupuncture for Pain
https://www.aafp.org/afp/2019/0715/p89.html
American Family Physician; Kelly, R. et. al.

Jul 14th, 2019 - Acupuncture has been increasingly used as an integrative or complementary therapy for pain. It is well-tolerated with little risk of serious adverse effects. Traditional acupuncture and nontraditional techniques, such as electroacupuncture and dry needling, often result in reported pain improvement. Multiple factors may contribute to variability in acupuncture's therapeutic effects, including n...

Does periodontitis represent a risk factor for rheumatoid arthritis? A systematic review and meta-analysis
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6620730/
Therapeutic Advances in Musculoskeletal Disease; Ferreira, R. et. al.

Jul 8th, 2019 - Periodontitis is an inflammatory disease of dental supporting tissues (gingiva, periodontal ligament, and bone) and it has been suggested as a possible etiology for rheumatoid arthritis (RA). In this systematic review, we aim to verify if periodontitis represents a risk factor for RA. Electronic databases were consulted until March 2018 considering eligibility criteria focusing on: (P, particip...

Psoriatic arthritis - Genetics Home Reference - NIH
https://ghr.nlm.nih.gov/condition/psoriatic-arthritis

Jul 8th, 2019 - Psoriatic arthritis is a condition involving joint inflammation (arthritis) that usually occurs in combination with a skin disorder called psoriasis. Psoriasis is a chronic inflammatory condition characterized by patches of red, irritated skin that are often covered by flaky white scales. People with psoriasis may also have changes in their fingernails and toenails, such as nails that become pi...